| For: | Watson NF, Durrant LG, Scholefield JH, Madjd Z, Scrimgeour D, Spendlove I, Ellis IO, Patel PM. Cytoplasmic expression of p27kip1 is associated with a favourable prognosis in colorectal cancer patients. World J Gastroenterol 2006; 12(39): 6299-6304 [PMID: 17072952 DOI: 10.3748/wjg.v12.i39.6299] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i39/6299.htm |
| Number | Citing Articles |
| 1 |
Timothy J. Duncan, Ahmad Al-Attar, Phil Rolland, Sarah Harper, Ian Spendlove, Lindy G. Durrant. Cytoplasmic p27 Expression is an Independent Prognostic Factor in Ovarian Cancer. International Journal of Gynecological Pathology 2010; 29(1) doi: 10.1097/PGP.0b013e3181b64ec3
|
| 2 |
Mohamed J. Saadh, Nada Khairi Younis, Abdulkareem Shareef, S. Renuka Jyothi, Priya Priyadarshini Nayak, Ashish Singh Chauhan, Siya Singla, Muborak Mamatova, Hayder Naji Sameer, Ahmed Yaseen, Zainab H. Athab, Mohaned Adil. Two small keys to a locked gate: miR-221/222 unlock immune escape and chemoresistance. Advances in Cancer Biology - Metastasis 2026; 17 doi: 10.1016/j.adcanc.2026.100187
|
| 3 |
Shuji Ogino, Kaori Shima, Katsuhiko Nosho, Natsumi Irahara, Yoshifumi Baba, Brian M. Wolpin, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Charles S. Fuchs. A Cohort Study of p27 Localization in Colon Cancer, Body Mass Index, and Patient Survival. Cancer Epidemiology, Biomarkers & Prevention 2009; 18(6) doi: 10.1158/1055-9965.EPI-09-0181
|
| 4 |
Dan D Hershko. Cyclin-Dependent Kinase Inhibitor p27 As a Prognostic Biomarker and Potential Cancer Therapeutic Target. Future Oncology 2010; 6(12) doi: 10.2217/fon.10.144
|
| 5 |
Isabel M. Chu, Ludger Hengst, Joyce M. Slingerland. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews Cancer 2008; 8(4) doi: 10.1038/nrc2347
|
| 6 |
Roger W. McGilvray, Robert A. Eagle, Nicholas F.S. Watson, Ahmad Al-Attar, Graham Ball, Insiya Jafferji, John Trowsdale, Lindy G. Durrant. NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting. Clinical Cancer Research 2009; 15(22) doi: 10.1158/1078-0432.CCR-09-0991
|
| 7 |
Tai-Yu Lai, Chia-Jui Yen, Hung-Wen Tsai, Yu-San Yang, Wei-Fu Hong, Chi-Wu Chiang. The B56γ3 regulatory subunit-containing protein phosphatase 2A outcompetes Akt to regulate p27KIP1 subcellular localization by selectively dephosphorylating phospho-Thr157 of p27KIP1. Oncotarget 2016; 7(4) doi: 10.18632/oncotarget.6609
|
| 8 |
Adriana Borriello, Debora Bencivenga, Maria Criscuolo, Ilaria Caldarelli, Valeria Cucciolla, Annunziata Tramontano, Alessia Borgia, Annamaria Spina, Adriana Oliva, Silvio Naviglio, Fulvio Della Ragione. Targeting p27Kip1protein: its relevance in the therapy of human cancer. Expert Opinion on Therapeutic Targets 2011; 15(6) doi: 10.1517/14728222.2011.561318
|
| 9 |
NEVYANA R. HRISTOVA, KATRIN E. TAGSCHERER, ANNE FASSL, JUERGEN KOPITZ, WILFRIED ROTH. Notch1-dependent regulation of p27 determines cell fate in colorectal cancer. International Journal of Oncology 2013; 43(6) doi: 10.3892/ijo.2013.2140
|
| 10 |
Jackie L. Ha, Erin Kaser, Tianyun Guan, Trenton G. Mayberry, Luke A. Smith, Kyle D’mello, Qian Bai, Mark R. Wakefield, Lijun Dong, Yujiang Fang. Up and away with cervical cancer: IL-29 is a promising cytokine for immunotherapy of cervical cancer due to its powerful upregulation of p18, p27, and TRAILR1. Medical Oncology 2024; 41(3) doi: 10.1007/s12032-023-02276-3
|